FDA Drug Recalls

Recalls / Class II

Class IID-0538-2025

Product

PROLIA (denosumab), injection, 60mg/mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-710-21

Brand name
Prolia
Generic name
Denosumab
Active ingredient
Denosumab
Route
Subcutaneous
NDC
55513-710
FDA application
BLA125320
Affected lot / code info
Lot: 1180924, Expiration date: 6/30/2027.

Why it was recalled

CGMP Deviations; potential temperature excursions due to transit delays

Recalling firm

Firm
Mckesson Medical-Surgical Inc. Corporate Office
Manufacturer
Amgen, Inc
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
9954 Maryland Drive, Deep Run Iii Ste. 4000, Richmond, Virginia 23233

Distribution

Quantity
6 Pre-filled syringes
Distribution pattern
Within the U.S - OH, VA, FL.

Timeline

Recall initiated
2025-04-21
FDA classified
2025-07-21
Posted by FDA
2025-07-30
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0538-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Prolia · FDA Drug Recalls